Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-030936
Filing Date
2024-08-09
Accepted
2024-08-09 15:09:39
Documents
45
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1069453
2 ex31-1.htm EX-31.1 17693
3 ex31-2.htm EX-31.2 18132
4 ex32-1.htm EX-32.1 7047
5 ex32-2.htm EX-32.2 6973
  Complete submission text file 0001493152-24-030936.txt   4584644

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE thar-20240630.xsd EX-101.SCH 24668
7 XBRL CALCULATION FILE thar-20240630_cal.xml EX-101.CAL 27491
8 XBRL DEFINITION FILE thar-20240630_def.xml EX-101.DEF 112072
9 XBRL LABEL FILE thar-20240630_lab.xml EX-101.LAB 286931
10 XBRL PRESENTATION FILE thar-20240630_pre.xml EX-101.PRE 224136
47 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 679842
Mailing Address 245 MAIN STREET SUITE 204 CHESTER NJ 07930
Business Address 1200 ROUTE 22 EAST BRIDGEWATER NJ 08807 302-743-2995
Tharimmune, Inc. (Filer) CIK: 0001861657 (see all company filings)

EIN.: 842642541 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41210 | Film No.: 241192155
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)